Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety study of 13-valent pneumococcal conjugate vaccine in elderly adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
2007-002683-10Phase 3Completed
- Sponsor
- Wyeth
- Start
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Wyeth. Primary endpoint: Safety objective. Started Jan 2008; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2007-002683-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002683-10.